BiotechTube

ZN-c3 + Bevacizumab + Pembrolizumab

Phase 1Withdrawn
1 views this week 0 watching💤 Quiet
Interest: 11/100
11
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Tumors

Conditions

Tumors, Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer

Trial Timeline

Dec 14, 2022 → Dec 14, 2022

NCT ID
NCT05431582

About ZN-c3 + Bevacizumab + Pembrolizumab

ZN-c3 + Bevacizumab + Pembrolizumab is a phase 1 stage product being developed by Zentalis Pharmaceuticals for Tumors. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05431582. Target conditions include Tumors, Ovarian Cancer, Breast Cancer.

What happened to similar drugs?

8 of 20 similar drugs in Tumors were approved

Approved (8) Terminated (4) Active (8)
✅Everolimus (RAD001)NovartisApproved
✅everolimusNovartisApproved
✅Imatinib MesylateNovartisApproved
✅NilotinibNovartisApproved
✅Sacituzumab Govitecan-hiyGilead SciencesApproved
✅Binimetinib only treatment + Encorafenib only Treatment + Encorafenib & Binimetinib Treatment + Treatment of Encorafenib & Binimetinib & Ribociclib + Treatment of Encorafenib & Binimetinib & CetuximabPfizerApproved
✅Sunitinib Malate (SU011248)PfizerApproved

Hype Score Breakdown

Clinical
6
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05431582Phase 1Withdrawn

Competing Products

20 competing products in Tumors

See all competitors
ProductCompanyStageHype Score
mRNA-4359ModernaPhase 2
0
mRNA-4106ModernaPhase 1
0
mRNA-4157 + Pembrolizumab + SoC TreatmentMerckPhase 1
33
E7050EisaiPhase 1
29
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
11
CixutumumabEli LillyPhase 1
29
[203Pb]VMT-α-NET + [212Pb]VMT-α-NETPerspective TherapeuticsPhase 1/2
33
[212Pb] VMT-α-NETPerspective TherapeuticsPhase 1
27
IMC-18F1Eli LillyPhase 1
29
OKI-179OnKure TherapeuticsPhase 1
19
ACR-2316Acrivon TherapeuticsPhase 1
26
LY2875358 + Erlotinib + GefitinibEli LillyPhase 1
29
Tomivosertib (eFT-508)eFFECTOR TherapeuticsPhase 2
25
SPYK04Chugai PharmaceuticalPhase 1
33
AUBE00 + CetuximabChugai PharmaceuticalPhase 1
36
LUNA18 + CetuximabChugai PharmaceuticalPhase 1
21
ERY974Chugai PharmaceuticalPhase 1
29
DS3610aDaiichi SankyoPhase 1
36
Tivantinib (ARQ 197) Capsule + Tivantinib (ARQ 197) Tablet + Tivantinib (ARQ 197) Capsule D, oralDaiichi SankyoPhase 1
29
DS-1123Daiichi SankyoPhase 1
29